Results 251 to 260 of about 18,452 (302)
Some of the next articles are maybe not open access.
Endothelin receptor antagonists
Pharmacology & Therapeutics, 2006Endothelin receptor antagonists (ERAs) have been developed to block the effects of endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful vasoconstrictor with mitogenic or co-mitogenic properties, which acts through the stimulation of 2 subtypes of receptors [endothelin receptor subtype A (ETA) and endothelin receptor subtype
Motte, Sophie +2 more
openaire +5 more sources
The endothelin system and endothelin receptor antagonists
Current Opinion in Nephrology & Hypertension, 2012There is increasing evidence that endothelin receptor blockade and, in particular, ET(A) receptor blockade not only confers protection against proteinuric renal disease in diabetes but also confers vasculoprotection.Recent clinical trials using ET(A) receptor blockade in treating proteinuria and chronic kidney disease as well as atherosclerosis show ...
Anna M.D. Watson, Karin Jandeleit-Dahm
openaire +3 more sources
Endothelin Receptor Antagonists - An Overview
Current Medicinal Chemistry, 2002In thirteen years since the appearance of Endothelin (ET) on the international scene, possibility of its involvement in a variety of diseases has attracted the attention of medicinal chemists in search of novel therapeutics for various cardiovascular diseases (CVDs).
Ashis K. Mukherjee +2 more
openaire +3 more sources
Peptoids as endothelin receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2001A series of new peptoids as endothelin receptor antagonists has been synthesized. Screening them for their ability to bind with endothelin receptors (ET(A) and ET(B)) competitively in the presence of (125I) endothelin led to the discovery of compounds as possible leads with IC50s in the low micromolar concentrations.
Simi Sarin +5 more
openaire +3 more sources
Endothelin Receptor Antagonists
2013Three pathways have been identified in the pathogenesis of pulmonary arterial hypertension (PAH): the endothelin (ET), nitric oxide (NO) and prostacyclin pathways. These pathways represent the targets of approved PAH therapies and their discovery has facilitated significant progress in the understanding and treatment of PAH.
Alessandro Maresta +3 more
openaire +3 more sources
Endothelin receptor antagonist for subarachnoid haemorrhage
Cochrane Database of Systematic Reviews, 2010A subarachnoid hemorrhage (SAH) is a serious and potentially life-threatening condition where blood leaks out of blood vessels over the surface of the brain. Delayed ischemic neurological deficit (DIND) and the related feature of vasospasm, where patients experience a delayed deterioration, have long been recognized as the leading potentially treatable
Lei Jiang +4 more
openaire +4 more sources
Endothelin receptor antagonists
World Journal of Urology, 2005Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression. New targets and new therapies are demanded. Through a review of the available literature on endothelin and several preclinical observations, the endothelin axis has emerged as one such target.
openaire +3 more sources
Endothelin, endothelin receptors, and endothelin antagonists
Current Opinion in Nephrology and Hypertension, 1994Endothelin is a peptide with potent biologic effects in vascular and nonvascular cells. Its effects are mediated by two receptors, ETA and ETB, and possibly also by a third receptor, ETC. In vascular smooth muscle cells, endothelin causes profound contraction and also has proliferative effects, mainly through activation of ETA but also through ETB ...
openaire +3 more sources
Thiophenesulfonamides as endothelin receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 1996AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Adam Kois +6 more
openaire +3 more sources
Bosentan: a dual endothelin receptor antagonist
Expert Opinion on Investigational Drugs, 2002The peptide endothelin plays a significant role in a wide array of pathological conditions, including primary pulmonary hypertension and pulmonary arterial hypertension associated with collagen vascular disease. These are life-threatening conditions that can severely compromise the function of the lungs and heart.
Sébastien Roux, Lewis J. Rubin
openaire +2 more sources